STAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on February 19, 2025
STAAR Surgical Company (
NASDAQSTAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended December 27, 2024, on or about Wednesday, February 19 after the market close.
STAAR Surgical to Participate in BTIG Ophthalmology Day
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors and a fireside chat at the 4th Annual BTIG Ophthalmology Day.
STAAR Surgical to Participate in Stephens Annual Investment Conference (NASH2024)
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with STAAR Management at the upcoming Stephens Annual Investment Conference, which will be held in Nashville, TN.
CORRECTING and REPLACING STAAR Surgical Reports Third Quarter 2024 Results
The end of the paragraph after bullets in the "Outlook" section of release should read: APAC sales growth of 5% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%) and all other APAC countries approximately 10-20% growth (prior outlook was flat). (Instead of: APAC sales growth of 4% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%).
STAAR Surgical to Report Third Quarter Results on October 30, 2024
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the third quarter ended September 27, 2024, on Wednesday, October 30, 2024, after the market close.
STAAR Surgical Experience Center Expands to Meet Growing Surgeon Demand
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICLTM) for myopia, astigmatism and presbyopia, is proud to announce the expansion and new location of the STAAR Surgical Experience Center. Located at STAAR’s headquarters in Lake Forest, California, near John Wayne Airport (SNA), the center serves as a dynamic hub for comprehensive, hands-on training and education in lens-based vision correction.
Sidoti Events, LLC's Virtual September Small-Cap ConferenceNEW YORK, NY / ACCESSWIRE / September 17, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day September Small-Cap Conference taking place Wednesday and Thursday, September 18-19, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
STAAR Surgical Reports Second Quarter 2024 Results
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the second quarter ended June 28, 2024.
STAAR Surgical to Report Second Quarter Results on August 7, 2024
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the second quarter ended June 28, 2024, on Wednesday, August 7, 2024, after the market close.
STAAR Surgical to Participate in Canaccord Genuity 44th Annual Growth Conference
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Canaccord Genuity 44th Annual Growth Conference, which will be held in Boston, Massachusetts.
Top 4 Stocks With Notable Insider BuyingInsider buying might signal confidence and a bullish outlook for investors. Four stocks with heavy insider buying include DLTR, TALO, STAA, and RXO.
STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference, which will be held in Miami, Florida.
STAAR Surgical Reports First Quarter 2024 Results
STAAR Surgical Company (
NASDAQK), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.
STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announces another milestone achieved on its U.S. Highway 93 go-to-market program – a strategic agreement with IQ Laser Vision, a leader in providing clear vision to clients with locations across California and Texas, and a top EVO ICL practice in North America.
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General CounselSTAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company’s executive committee and report to Tom Frinzi, STAAR Surgical’s President and CEO.
STAAR Surgical to Report First Quarter Results on May 7, 2024
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.
Star Surgical Shines as U.S. Outlook Improves for 2024STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter. This represents the Company’s highest quarterly ICL sales in the U.S. since the Company obtained U.S. FDA approval of the EVO ICL in March 2022. The Company is providing this information due to investment community meetings taking place April 5-8 at the ASCRS Annual Meeting in Boston.
STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, comes to the American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in Boston from April 5-8, 2024, fresh off the achievement of a new commercial milestone: three million lenses sold. Furthering the momentum behind its flagship product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters, presentations and educational programs. STAAR Surgical can be found at Booth 527 and additional ASCRS event information is available at https://ascrs.org/annual-meeting.
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1
STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, effective March 12, 2024.
STAAR Surgical to Participate in Two Upcoming Investor Conferences
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors at the following conferences:
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the fourth quarter and fiscal year ended December 29, 2023.
STAAR Surgical to Report Fourth Quarter Results on February 26, 2024
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close.
STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision
STAAR Surgical Company (
NASDAQSTAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, and SharpeVision, a premier ophthalmology group with clinics in Seattle, Chicago and Austin, today announced a strategic agreement to provide EVO ICL lenses as a first choice for patients seeking visual freedom from contact lenses and glasses.
